recently announced a strategic deal with Epizyme, Inc. for the
development of a molecular companion diagnostic test for use with
EPZ-5676 is being developed by Epizyme for the treatment of
mixed lineage leukemia (MLL-r).
Under this deal, Abbott Labs will use its fluorescence in
situhybridization (FISH) technology to develop the test. It will
help in identifying patients eligible for treatment with
Epizyme's EPZ-5676. Financial details of the deal were not
In Feb 2013, Abbott Labs collaborated with
Johnson & Johnson's
) Janssen Biotech, Inc. and
Pharmacyclics, Inc. (
to use Abbott Labs' proprietary FISH technology for developing a
molecular companion diagnostic test that will help identify
patients with a genetic subtype of chronic lymphocytic leukemia
The FISH-based test will be used for the identification of
high-risk CLL patients who are more likely to respond to
ibrutinib. Ibrutinib is being developed for several B-cell
malignancies including chronic leukemia and lymphoma.
Pharmacyclics expects to file a New Drug Application (NDA) with
the US Food and Drug Administration (FDA) for the use of
ibrutinib in patients with relapsed or refractory mantle cell
lymphoma (MCL) before the end of 2013.
We note that Abbott Labs separated its business into two
publicly-traded companies on Jan 1, 2013 - one in diversified
medical products and the other in research-based
Abbott Labs is extremely diversified with attractive nutrition
and diagnostics businesses. AbbottLabs carries a Zacks Rank #3
(Hold). Right now,
NuVasive, Inc. (
looks more attractive with a Zacks Rank #1 (Strong Buy).
ABBOTT LABS (ABT): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis
NUVASIVE INC (NUVA): Free Stock Analysis
PHARMACYCLICS (PCYC): Free Stock Analysis
To read this article on Zacks.com click here.